LG 101506: Precision RXR Modulator for Nuclear Receptor Signaling Research

Executive Summary: LG 101506 is a small molecule Retinoid X Receptor (RXR) modulator with 98% purity and defined solubility parameters, enabling reproducible research in RXR signaling (APExBIO). It is chemically characterized as (2E,4E,6Z)-7-(3,5-di-tert-butyl-2-(2,2-difluoroethoxy)phenyl)-3-methylocta-2,4,6-trienoic acid, with a molecular weight of 420.53 g/mol. LG 101506 is suitable for studies in metabolism, nuclear receptor signaling, and cellular signaling pathways, especially within the context of immuno-oncology (Zhang et al. 2022). Products ship under temperature-controlled conditions to maintain molecular integrity. Usage is strictly limited to scientific research; it is not for diagnostic or therapeutic applications (APExBIO).

Biological Rationale

Retinoid X Receptors (RXRs) are nuclear receptors that regulate gene transcription in response to endogenous ligands and synthetic modulators. RXR forms heterodimers with other nuclear receptors such as PPAR, LXR, and RAR, impacting diverse cellular processes including lipid metabolism, glucose homeostasis, and cellular differentiation (Zhang et al. 2022). Abnormal RXR signaling has been implicated in metabolic disorders and cancer, including triple-negative breast cancer (TNBC), where immune checkpoint evasion is prominent. Modulation of RXR pathways can influence the expression of immune-regulatory proteins, such as PD-L1, and thus is of high interest for immunometabolic and cancer biology research (Further reading). This article extends the discussion by detailing LG 101506's role in dissecting RXR-mediated control over PD-L1 expression and immune-cold tumor microenvironments, as highlighted in recent benchmarks.

Mechanism of Action of LG 101506

LG 101506 acts as a selective RXR modulator. Upon binding RXR, it induces conformational changes that influence RXR heterodimerization with partner receptors and subsequent recruitment of coactivators or corepressors. This modulation alters the transcription of downstream target genes, including those involved in metabolism and immune regulation (Zhang et al. 2022). In immune-cold cancers such as TNBC, RXR signaling intersects with key immune checkpoint pathways, such as PD-L1/PD-1. LG 101506 enables precise experimental control over these axes, supporting research into mechanisms of immune evasion and metabolic adaptation in the tumor microenvironment (Compare to detailed workflow guide).

Evidence & Benchmarks

• LG 101506 demonstrates high solubility: 42.05 mg/ml in DMSO and 21.03 mg/ml in ethanol, supporting flexible experimental design (APExBIO).
• Product purity is validated at 98.00% by HPLC, ensuring batch-to-batch consistency (APExBIO).
• RXR modulation has been shown to regulate PD-L1 expression, a key immune checkpoint in cancer (Zhang et al. 2022, Fig. 1).
• Loss of RXR pathway function impairs the regulation of B4GALT1 and subsequent PD-L1 glycosylation, influencing T cell-mediated anti-tumor immunity (Zhang et al. 2022, Results section).
• LG 101506 empowers researchers to dissect nuclear receptor signaling in advanced disease models, extending the findings of prior RXR ligand studies (See expert strategies).

Applications, Limits & Misconceptions

LG 101506 is designed for research applications involving RXR signaling, including studies of metabolism regulation, immune checkpoint biology, and cancer models. It is particularly valuable for dissecting the mechanistic basis of immune-cold tumor resistance to immunotherapies. This article updates previous content by focusing on the molecular benchmarks and practical solubility limits relevant to immunometabolic workflows (Earlier overview).

Common Pitfalls or Misconceptions

• LG 101506 is not suitable for human or veterinary diagnostic or therapeutic use; it is strictly for laboratory research (APExBIO).
• Long-term storage of LG 101506 solutions is not recommended; use prepared solutions promptly to avoid degradation.
• The compound should be stored at -20°C without repeated freeze-thaw cycles to maintain purity and activity.
• Experimental conditions (e.g., solvent, temperature, buffer) must match solubility and stability parameters for reproducibility.
• LG 101506 modulates RXR but does not directly inhibit downstream immune checkpoints like PD-L1; its effects are mediated through transcriptional regulation.

Workflow Integration & Parameters

LG 101506 (B7414) is supplied as an off-white solid and ships with blue ice or dry ice depending on format, ensuring sample integrity (APExBIO). For in vitro use, dissolve in DMSO (up to 42.05 mg/ml) or ethanol (up to 21.03 mg/ml). Solutions should be freshly prepared and used promptly. For accurate dosing, verify solubility at the working temperature and buffer composition. For RXR signaling assays, typical working concentrations range from 0.1–10 μM, though optimization is recommended for each model system. LG 101506 is compatible with nuclear receptor reporter assays, metabolic flux analysis, and immune modulation studies. This workflow complements prior protocols by emphasizing precise control of RXR axis manipulation in immune-cold tumor models (Contrast: expanded troubleshooting).

Conclusion & Outlook

LG 101506 is a next-generation RXR modulator, enabling precision research in nuclear receptor signaling and immunometabolic disease models. By offering validated purity, solubility, and workflow compatibility, it supports rigorous interrogation of RXR pathway function, particularly in the context of cancer immune evasion. For further technical specifications or to order the B7414 kit, visit the official LG 101506 product page at APExBIO. Future work will clarify its utility in optimizing combinatorial immunotherapy strategies and metabolic pathway dissection, building on recent advances in RXR-mediated regulation of immune checkpoints.